Blagosklonny M
Oncoscience. 2024; 11:1-14.
PMID: 38188499
PMC: 10765422.
DOI: 10.18632/oncoscience.593.
Valentova J, Lintnerova L, Miklasova N, Obonova B, Habala L
Int J Mol Sci. 2023; 24(6).
PMID: 36982753
PMC: 10058835.
DOI: 10.3390/ijms24065679.
Blagosklonny M
Oncotarget. 2021; 12(18):1821-1835.
PMID: 34504654
PMC: 8416555.
DOI: 10.18632/oncotarget.28049.
Lou S, Zhao Z, Dezort M, Lohneis T, Zhang C
ACS Omega. 2018; 3(8):9210-9219.
PMID: 30197996
PMC: 6120734.
DOI: 10.1021/acsomega.8b00949.
Kawaguchi K, Miyake K, Zhao M, Kiyuna T, Igarashi K, Miyake M
Cell Cycle. 2018; 17(16):2019-2026.
PMID: 29963961
PMC: 6224272.
DOI: 10.1080/15384101.2018.1480223.
Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
Igarashi K, Kawaguchi K, Li S, Han Q, Tan Y, Gainor E
Oncotarget. 2018; 9(27):19263-19272.
PMID: 29721200
PMC: 5922394.
DOI: 10.18632/oncotarget.24996.
Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
Kawaguchi K, Miyake K, Han Q, Li S, Tan Y, Igarashi K
Cell Cycle. 2018; 17(7):868-873.
PMID: 29623758
PMC: 6056209.
DOI: 10.1080/15384101.2018.1445907.
Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models.
Kawaguchi K, Han Q, Li S, Tan Y, Igarashi K, Miyake K
Oncotarget. 2018; 9(13):11119-11125.
PMID: 29541401
PMC: 5834286.
DOI: 10.18632/oncotarget.24264.
Genetic and metabolic comparison of orthotopic and heterotopic patient-derived pancreatic-cancer xenografts to the original patient tumors.
Jun E, Hong S, Yoo H, Kim M, Won J, An S
Oncotarget. 2018; 9(8):7867-7881.
PMID: 29487698
PMC: 5814265.
DOI: 10.18632/oncotarget.23567.
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.
Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Li Y
Oncotarget. 2018; 9(8):7774-7781.
PMID: 29487690
PMC: 5814257.
DOI: 10.18632/oncotarget.22892.
Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.
Kawaguchi K, Igarashi K, Li S, Han Q, Tan Y, Miyake K
Oncotarget. 2018; 9(1):915-923.
PMID: 29416666
PMC: 5787523.
DOI: 10.18632/oncotarget.23185.
Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients.
Kawaguchi K, Igarashi K, Kiyuna T, Miyake K, Miyake M, Murakami T
Cell Cycle. 2018; 17(5):627-633.
PMID: 29384032
PMC: 5969558.
DOI: 10.1080/15384101.2017.1421876.
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill....
Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Li S
Cell Cycle. 2018; 17(6):801-809.
PMID: 29374999
PMC: 5969544.
DOI: 10.1080/15384101.2018.1431596.
Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K, Kawaguchi K, Kiyuna T, Miyake M, Igarashi K, Zhang Z
Cell Cycle. 2018; 17(6):722-727.
PMID: 29334307
PMC: 5969563.
DOI: 10.1080/15384101.2017.1423223.
The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and deletion: Direction for third-line patient therapy.
Miyake K, Murakami T, Kiyuna T, Igarashi K, Kawaguchi K, Miyake M
Oncotarget. 2017; 8(61):103129-103136.
PMID: 29262551
PMC: 5732717.
DOI: 10.18632/oncotarget.20789.
Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.
Kawaguchi K, Han Q, Li S, Tan Y, Igarashi K, Kiyuna T
Cell Cycle. 2017; 17(3):356-361.
PMID: 29187018
PMC: 5914727.
DOI: 10.1080/15384101.2017.1405195.
Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K, Igarashi K, Li S, Han Q, Tan Y, Kiyuna T
Oncotarget. 2017; 8(49):85516-85525.
PMID: 29156737
PMC: 5689627.
DOI: 10.18632/oncotarget.20231.
Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Igarashi K, Kawaguchi K, Kiyuna T, Murakami T, Miwa S, Nelson S
Oncotarget. 2017; 8(44):75874-75880.
PMID: 29100276
PMC: 5652670.
DOI: 10.18632/oncotarget.16548.
A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology.
Igarashi K, Murakami T, Kawaguchi K, Kiyuna T, Miyake K, Zhang Y
Oncotarget. 2017; 8(37):62111-62119.
PMID: 28977930
PMC: 5617490.
DOI: 10.18632/oncotarget.19095.
A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX).
Igarashi K, Kawaguchi K, Murakami T, Kiyuna T, Miyake K, Yamamoto N
Oncotarget. 2017; 8(38):63353-63359.
PMID: 28968995
PMC: 5609927.
DOI: 10.18632/oncotarget.18806.
